FR2739557B1 - Utilisation d'un ligand agoniste specifique rar-gamma - Google Patents

Utilisation d'un ligand agoniste specifique rar-gamma

Info

Publication number
FR2739557B1
FR2739557B1 FR9512179A FR9512179A FR2739557B1 FR 2739557 B1 FR2739557 B1 FR 2739557B1 FR 9512179 A FR9512179 A FR 9512179A FR 9512179 A FR9512179 A FR 9512179A FR 2739557 B1 FR2739557 B1 FR 2739557B1
Authority
FR
France
Prior art keywords
rar
specific agonist
agonist ligand
gamma specific
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9512179A
Other languages
English (en)
Other versions
FR2739557A1 (fr
Inventor
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Centre International de Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9512179A priority Critical patent/FR2739557B1/fr
Application filed by Centre International de Recherches Dermatologiques Galderma filed Critical Centre International de Recherches Dermatologiques Galderma
Priority to HU9900453A priority patent/HUP9900453A3/hu
Priority to CN96198769A priority patent/CN1121857C/zh
Priority to CA002231561A priority patent/CA2231561A1/fr
Priority to AU72209/96A priority patent/AU705993B2/en
Priority to BR9610967A priority patent/BR9610967A/pt
Priority to PL96326077A priority patent/PL185826B1/pl
Priority to NZ319646A priority patent/NZ319646A/xx
Priority to EP96933502A priority patent/EP0854710A2/fr
Priority to RU98108590/14A priority patent/RU2188037C2/ru
Priority to KR1019980702620A priority patent/KR19990064139A/ko
Priority to PCT/FR1996/001568 priority patent/WO1997013505A2/fr
Priority to TR1998/00645T priority patent/TR199800645T1/xx
Priority to US09/051,407 priority patent/US6593359B1/en
Priority to JP09514767A priority patent/JP3135266B2/ja
Publication of FR2739557A1 publication Critical patent/FR2739557A1/fr
Publication of FR2739557B1 publication Critical patent/FR2739557B1/fr
Application granted granted Critical
Priority to NO981592A priority patent/NO981592L/no
Priority to US09/431,920 priority patent/US6686386B1/en
Priority to US09/624,771 priority patent/US6506796B1/en
Priority to US09/801,664 priority patent/US20010018456A1/en
Priority to US10/183,518 priority patent/US20030092758A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR9512179A 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma Expired - Fee Related FR2739557B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma
TR1998/00645T TR199800645T1 (xx) 1995-10-09 1996-10-08 Apoptoz oran�n�n artt�r�lmas� i�in bir y-RAR-�zg� agonist ligand�n�n kullan�m�.
CA002231561A CA2231561A1 (fr) 1995-10-09 1996-10-08 Utilisation d'un ligand agoniste specifique rar-.gamma. pour augmenter le taux d'apoptose
AU72209/96A AU705993B2 (en) 1995-10-09 1996-10-08 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
BR9610967A BR9610967A (pt) 1995-10-09 1996-10-08 Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele
PL96326077A PL185826B1 (pl) 1995-10-09 1996-10-08 Zastosowanie specyficznego ligandu agonistycznegoZastosowanie specyficznego ligandu agonistycznegoRAR-y do zwiększenia stopnia apoptozyRAR-y do zwiększenia stopnia apoptozy
NZ319646A NZ319646A (en) 1995-10-09 1996-10-08 Use of a rar-y-specific agonist ligand for increasing the rate of apoptosis
CN96198769A CN1121857C (zh) 1995-10-09 1996-10-08 RAR－γ特异性激动剂配体用于提高细胞程序死亡率
RU98108590/14A RU2188037C2 (ru) 1995-10-09 1996-10-08 ИСПОЛЬЗОВАНИЕ АГОНИСТА-ЛИГАНДА, СПЕЦИФИЧНОГО ДЛЯ РЕЦЕПТОРОВ ТИПА RAR-γ, ДЛЯ УВЕЛИЧЕНИЯ СКОРОСТИ АПОПТОЗА
KR1019980702620A KR19990064139A (ko) 1995-10-09 1996-10-08 세포 소멸 속도를 증가시키는 감마-알에이알-특이성 작용 물질리간드의 용도
HU9900453A HUP9900453A3 (en) 1995-10-09 1996-10-08 Use of a gamma-rar-specific agonist ligand to increase apoptosis rate
PCT/FR1996/001568 WO1997013505A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE
EP96933502A EP0854710A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-$g(g) POUR AUGMENTER LE TAUX D'APOPTOSE
JP09514767A JP3135266B2 (ja) 1995-10-09 1996-10-08 アポプトシス速度向上のためのＲＡＲ−γ−特異的アゴニストリガンドの使用
US09/051,407 US6593359B1 (en) 1995-10-09 1996-10-08 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
NO981592A NO981592L (no) 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten
US09/431,920 US6686386B1 (en) 1995-10-09 1999-11-02 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
US09/624,771 US6506796B1 (en) 1995-10-09 2000-07-25 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
US09/801,664 US20010018456A1 (en) 1995-10-09 2001-03-09 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
US10/183,518 US20030092758A1 (en) 1995-10-09 2002-06-28 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma

Publications (2)

Publication Number Publication Date
FR2739557A1 FR2739557A1 (fr) 1997-04-11
FR2739557B1 true FR2739557B1 (fr) 1997-11-14

Family

ID=9483613

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9512179A Expired - Fee Related FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma

Country Status (16)

Country Link
US (4) US6593359B1 (fr)
EP (1) EP0854710A2 (fr)
JP (1) JP3135266B2 (fr)
KR (1) KR19990064139A (fr)
CN (1) CN1121857C (fr)
AU (1) AU705993B2 (fr)
BR (1) BR9610967A (fr)
CA (1) CA2231561A1 (fr)
FR (1) FR2739557B1 (fr)
HU (1) HUP9900453A3 (fr)
NO (1) NO981592L (fr)
NZ (1) NZ319646A (fr)
PL (1) PL185826B1 (fr)
RU (1) RU2188037C2 (fr)
TR (1) TR199800645T1 (fr)
WO (1) WO1997013505A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US20030053991A1 (en) * 2000-10-04 2003-03-20 Kingsman Alan John Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
KR20040031107A (ko) * 1997-11-12 2004-04-09 에프. 호프만-라 로슈 아게 레티노이드 길항제를 이용한 제2형 ｔ-보조세포 중재면역질환의 치료
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US20060151574A1 (en) * 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
US20050202055A1 (en) 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
WO2005092283A1 (fr) * 2004-03-26 2005-10-06 Dsm Ip Assets B.V. Composition comprenant un inhibiteur d'hdac combine a un retinoide
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9254162B2 (en) 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US8298216B2 (en) 2007-11-14 2012-10-30 Myoscience, Inc. Pain management using cryogenic remodeling
KR20110119640A (ko) 2008-12-22 2011-11-02 마이오우사이언스, 인크. 냉매 공급원과 전원이 통합된 한랭수술 시스템
MX361414B (es) * 2010-09-01 2018-12-05 Univ Jefferson Composición y método para reparación y regeneración muscular.
KR102164567B1 (ko) * 2011-06-24 2020-10-12 쥐알아이 바이오,아이엔씨. 염증 질환의 예방 및 치료
WO2013106859A1 (fr) 2012-01-13 2013-07-18 Myoscience, Inc. Aiguille cryogénique avec régulation de la zone de congélation
CA2861116A1 (fr) 2012-01-13 2013-07-18 Myoscience, Inc. Systeme de filtration de sonde cryogenique
CA2860893A1 (fr) 2012-01-13 2013-07-18 Myoscience, Inc. Protection de la peau pour le remodelage sous-cutane cryogenique dans le cadre de soins cosmetiques et autres traitements
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US10016229B2 (en) 2013-03-15 2018-07-10 Myoscience, Inc. Methods and systems for treatment of occipital neuralgia
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
CN105208954B (zh) 2013-03-15 2019-06-04 肌肉科技股份有限公司 低温钝性解剖方法和设备
US10130409B2 (en) 2013-11-05 2018-11-20 Myoscience, Inc. Secure cryosurgical treatment system
ES2898676T3 (es) 2015-11-25 2022-03-08 Io Therapeutics Inc Agonistas selectivos de rar-alfa resistentes a CYP26 en el tratamiento del cáncer
US11311327B2 (en) 2016-05-13 2022-04-26 Pacira Cryotech, Inc. Methods and systems for locating and treating nerves with cold therapy
EP3468600A4 (fr) 2016-06-10 2019-11-13 IO Therapeutics, Inc. Composés rétinoïdes et rexinoïdes sélectifs du récepteur et modulateurs immunitaires pour l'immunothérapie du cancer
KR20200029544A (ko) 2017-07-13 2020-03-18 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
WO2019099677A1 (fr) 2017-11-15 2019-05-23 Myoscience, Inc. Systèmes intégrés de thérapie à froid et de stimulation électrique pour localiser et traiter des nerfs et procédés associés
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786391A (en) * 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
EP0850067A4 (fr) 1995-07-17 1999-12-15 Cird Galderma Procedes de traitement de cancers a l'aide de 6- 3- 1-adamantyl]-4-hydroxyphenyl]

Also Published As

Publication number Publication date
NZ319646A (en) 2000-08-25
JP3135266B2 (ja) 2001-02-13
FR2739557A1 (fr) 1997-04-11
CN1121857C (zh) 2003-09-24
RU2188037C2 (ru) 2002-08-27
US20010018456A1 (en) 2001-08-30
EP0854710A2 (fr) 1998-07-29
BR9610967A (pt) 1999-03-02
WO1997013505A2 (fr) 1997-04-17
CA2231561A1 (fr) 1997-04-17
PL185826B1 (pl) 2003-08-29
HUP9900453A2 (hu) 1999-05-28
TR199800645T1 (xx) 1998-06-22
HUP9900453A3 (en) 1999-11-29
NO981592L (no) 1998-06-09
AU705993B2 (en) 1999-06-03
PL326077A1 (en) 1998-08-17
KR19990064139A (ko) 1999-07-26
JPH11501661A (ja) 1999-02-09
US6593359B1 (en) 2003-07-15
US6506796B1 (en) 2003-01-14
US6686386B1 (en) 2004-02-03
CN1203528A (zh) 1998-12-30
AU7220996A (en) 1997-04-30
NO981592D0 (no) 1998-04-07
WO1997013505A3 (fr) 1997-05-29

Similar Documents

Publication Publication Date Title
FR2739557B1 (fr) Utilisation d&#39;un ligand agoniste specifique rar-gamma
PT811006E (pt) Compostos contendo benzopirano e metodos para a sua utilizacao
FR2739707B1 (fr) Dispositif d&#39;edition cartographique
DE69625739T2 (de) Schlauchaufbau enthaltend Fluorterpolymere
NO980216D0 (no) Telefonsentral
FR2750518B1 (fr) Lanceur d&#39;applications securise a interface graphique
FR2730572B1 (fr) Dispositif d&#39;interface
DK12196A (da) Ristkøler
FR2731733B1 (fr) Parpaing portable a la main
FR2738473B1 (fr) Dispositif d&#39;electro-physiologie
FR2723701B3 (fr) Utilisation d&#39;un granulateur et granulateur correspondant
FR2739308B1 (fr) Dispositif d&#39;essuyage-aspiration d&#39;une surface
FR2732190B1 (fr) Composition fongicide a base de prochloraze et d&#39;un compose triazole
FR2723702B1 (fr) Dispositif d&#39;enduction
FR2732057B1 (fr) Dispositif de suspension d&#39;un element de construction
FR2728403B1 (fr) Dispositif de suspension mobile d&#39;un cable
FR2771994B1 (fr) Embarcation a usage d&#39;habitation
FR2735986B3 (fr) Prolongateur d&#39;haltere
ITMI950895A0 (it) Livella a base prismatica per l&#39;edilizia
FR2747426B1 (fr) Agencement d&#39;escabeau a plate-forme autostable
FR2764209B1 (fr) Preparation d&#39;un catalyseur et utilisation de ce catalyseur pour la depollution d&#39;un effluent photographique
ITCE950003U1 (it) Sua maesta&#39; le frivol
FR2735197B1 (fr) Mousqueton de maintien d&#39;un cable de securite sur une structure
DE29500960U1 (de) Mehrzweckleiter
KR960030230U (ko) 휴대용 물통

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060630